Posts tagged clinics
Microbix meets FDA on Kinlytic return to U.S. market

Microbix Biosystems (TSX:MBX) has consulted with the FDA regarding the company's plans to return its thrombolytic biologic drug, Kinlytic, to the U.S. market.

Read More
Leerink starts American Renal at outperform

Leerink Partners has launched coverage of American Renal Associates (NYSE:ARA) with an “outperform” rating and $33 price target. The stock closed at $27.71 on Friday.

“Our positive thesis contemplates a forward adjusted EBITDA (excluding non-controlling interest) growth rate of 13% (2015-2019 estimated CAGR) and is based on three growth pillars,” writes analyst Ana Gupte.

Read More